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Differentially Modulate Keratinocyte
Proliferation: Possible Deregulation in
Psoriatic Epidermis
Rosa M. Andre´s1,2, Marı´a Carmen Terencio1,2, Jorge Arasa1,2, Miguel Paya´1,2,
Francisca Valcuende-Cavero3,4, Pedro Navalo´n5 and Marı´a Carmen Montesinos1,2Adenosine is a potent regulator of inflammation and immunity, but the role of adenosine receptors in kera-
tinocytes remains controversial. We determined that in addition to A2B receptors, human epidermal kerati-
nocytes also express A2A receptors, although to a lower extent. Through the use of selective adenosine receptor
agonists and antagonists, we showed that physiological concentrations of adenosine activate A2B receptors in
normal human keratinocytes, inducing cell cycle arrest through the increase of intracellular calcium but not
through cAMP signaling. In contrast, the selective activation of A2A receptors by CGS-21680 induces kerati-
nocyte proliferation via p38emitogen-activated protein kinase activation. Adenosine and selective A2A and A2B
agonists presented anti-inflammatory profiles independent of adenosine receptors but mediated by membrane
phosphatase activation. Finally, keratinocyte exposure to diverse inflammatory cytokines altered adenosine
receptor expression by reducing A2B and increasing A2A, a pattern also observed in psoriatic epidermis. Because
increased epidermal turnover and inflammatory response are characteristics of psoriatic disease, further
studies are needed to assess the role and consequences of the altered adenosine receptor expression in
lesional and nonlesional psoriatic keratinocytes.
Journal of Investigative Dermatology (2017) 137, 123e131; doi:10.1016/j.jid.2016.07.028INTRODUCTION
In the era of biologic therapies, the classic immunomodulator
methotrexate is still considered a first-line, inexpensive sys-
temic treatment of psoriasis with a very well-established
safety profile (Yelamos and Puig, 2015). Methotrexate is a
competitive inhibitor of dihydrofolate reductase, which
blocks DNA synthesis and cell mitosis of rapidly dividing
cells. However, folic acid supplements are co-administered
to reduce its toxicity and adverse effects without compro-
mising its anti-inflammatory efficacy, suggesting that other
mechanisms of actionmight exist (Bangert and Costner, 2007).
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studies have shown the involvement of adenosine (Chan and
Cronstein, 2010; Yelamos and Puig, 2015).
Adenosine is an endogenous purine nucleoside that can be
released or formed by enzymatic dephosphorylation of
adenosine triphosphate, adenosine diphosphate, and aden-
osine monophosphate during inflammation, wounding,
and other pathological states. Once in the extracellular
compartment, adenosine acts through four subtypes of
adenosine receptors (ARs), A1, A2A, A2B, and A3, all
belonging to the large family of G protein-associated
receptors (Fredholm et al., 2011). Numerous studies indi-
cate that adenosine is a potent regulator of inflammation and
immunity (Antonioli et al., 2014; Ernst et al., 2010). In
contrast, little is known about adenosine effects on epidermal
cells, and reports are often contradictory. Thus, activation of
adenosine A2B receptors promotes murine keratinocyte pro-
liferation (Braun et al., 2006), whereas adenosine inhibits
human keratinocyte proliferation through uptake by the cell
membrane transporter hENT1 (Brown et al., 2000).
Purinergic signaling in healthy and diseased skin has
emerged as a renewed area of interest (Burnstock et al.,
2012). In particular, activation of adenosine A2A receptor
plays an important role in promotion of wound healing
(Montesinos et al., 2015), being especially relevant in the
formation of new granulation tissue and revascularization of
the wound bed (Montesinos and Valls, 2010; Valls et al.,
2009). Although mice with a targeted disruption of this
receptor subtype showed a defect in granulation tissue for-
mation, wound re-epithelialization was hardly compromisedestigative Dermatology. www.jidonline.org 123
RM Andre´s et al.
Adenosine Receptors on Keratinocyte Function
124(Montesinos et al., 2002). Moreover, topical application of an
A2A agonist has proved to be beneficial, preventing
epidermal hyperplasia induced by repeated 12-O-tetradeca-
noylphorbol-13-acetate (TPA) treatment, showing an
anti-inflammatory effect (Arasa et al., 2014). In addition, this
receptor subtype could be involved in the murine
imiquimod-induced model of psoriasis, because imiquimod
has been also characterized as an A2A AR antagonist (Flutter
and Nestle, 2013; Schon et al., 2006). Furthermore, an A3 AR
agonist is currently being evaluated in phase II and III clinical
trials in patients with moderate to severe plaque psoriasis
because of its regulatory effect on T-cell function (David
et al., 2012; Kofoed et al., 2015).
In this study we have assessed the expression and signal
transduction mechanisms of AR in normal human epidermal
keratinocytes (NHEK). In addition, through the use of selec-
tive AR agonists and antagonists, we have shown a differen-
tial effect of A2B and A2A AR on cell proliferation and a
receptor-independent anti-inflammatory effect. Finally, we
have determined the possible influence of the inflammatory
milieu on AR expression in NHEK, which mimics the
expression of AR in psoriatic epidermis.
RESULTS
Adenosine A2B but not A2A receptor stimulation increases
intracellular cAMP and iCa2D in NHEK
Earlier reports indicated that A2B was the only AR subtype
expressed by NHEK (Brown et al., 2000), whereas, in murine
keratinocytes, lower expressions of A2A and A3 AR have also
been described (Braun et al., 2006). We analyzed the
expression of AR in NHEK by reverse transcriptase PCR and
confirmed that, although A2B is the major AR subtype
expressed by these cells (DCt against glyceraldehyde-
3-phosphate dehydrogenase ¼ 7.02  0.074, n ¼ 10), A2A
receptors are also expressed to a lesser extent (DCt against
glyceraldehyde-3-phosphate dehydrogenase ¼ 12.50  0.16,
n ¼ 12, P < 0.001 vs. A2B), whereas subtypes A1 and A3 were
undetectable (Figure 1a).
Both A2A and A2BARs are supposedly coupled to Gs proteins
and, thus, their activation increases intracellular cAMP, which
has been mainly associated with the anti-inflammatory
response of adenosine (Ernst et al., 2010). We incubated
NHEK with the selective A2A agonist CGS-21680 (CGS), the
selective A2B agonist BAY60e6583 (BAY), or the nonselective
agonist 5’-N-ethylcarboxamidoadenosine (NECA) alone or in
combinationwith the selective antagonists SCH-442416 (SCH)
and MRS-1706 (MRS) (see Supplementary Table S1 online).
After 15minutes, NECA andBAYinduced a significant increase
in the intracellular cAMP concentration that was inhibited by
the selective A2B antagonist MRS, indicating signaling through
Gs protein (Figure 1b). In contrast, CGS failed to induce cAMP
elevation, and the selective A2A antagonist SCH did not affect
NECA-induced production of cAMP, ruling out this second
messenger downstream of the A2A AR activation in NHEK.
Because A2B AR has also been reported to signal through
intracellular calcium (iCa2þ) via Gq protein activation in
certain cellular types (Aherne et al., 2011; Hasko´ et al.,
2008), we incubated NHEK with AR agonists and antago-
nists and determined iCa2þ levels by coupling with a fluo-
rescent dye. As shown in Figure 1c, stimulation with eitherJournal of Investigative Dermatology (2017), Volume 137the nonselective agonist NECA or the selective A2B agonist
BAY led to an increase in iCa2þ that was reversed by co-
incubation with the A2B antagonist MRS but not by the A2A
selective antagonist SCH; the A2A agonist CGS had no effect
at this level. These results are consistent with A2B AR
signaling through Gq in NHEK as well.
Adenosine A2A and A2B receptor subtypes differentially
modulate keratinocyte proliferation
Using selective AR agonists and antagonists, we found that
activation of A2A and A2B AR had opposing effects on NHEK
proliferation, determined by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) reduction. Thus,
incubation with the selective A2B agonist BAY decreased ker-
atinocyte proliferation, whereas the selective A2A agonist CGS
increased cell growth (Figure 2a), effects that were inhibited
by the selective antagonists MRS and SCH, respectively.
The nonselective agonist NECA, widely used in research as
an adenosine equivalent that does not suffer enzymatic
deamination, enhanced keratinocyte proliferation. This effect
was abrogated by the selective antagonist SCH, indicating the
involvement of A2A AR. Because it has been shown that
adenosine inhibited proliferation of NHEK (Brown et al.,
2000), we determined its effect in the presence or absence of
the selective antagonists. As shown in Figure 2a, the anti-
proliferative effect of adenosinewasprimarilymediated byA2B
AR, because it was abrogated by MRS. The opposing effects of
the nonselective agonist NECA and the endogenous ligand
adenosine are probably due to the higher affinity of NECA for
the A2A AR (see Supplementary Table S1) (Alnouri et al., 2015),
thus explaining the previously reported divergences regarding
the effect of AR activation on NHEK proliferation.
Cell proliferation results were confirmed by cell cycle
analysis. As shown in Figure 2b, A2A stimulation by CGS
significantly increased the fraction of cells in G2/M in
accordance with the increased cell proliferation observed by
MTT assay, even though there was no appreciable change in
the S phase. In contrast, A2B activation decreased S and G2/M
fraction while increasing G1, showing an antiproliferative
effect. These results were validated with selective AR antag-
onists (see Supplementary Figure S1 online). Similar to the
MTT assay, NECA and adenosine evidenced opposing effects
in the cell cycle mediated by A2A and A2B receptors,
respectively (Figure 2b, and see Supplementary Figure S1).
Opposite effects of A2A and A2B AR on the cell cycle are
mediated by p38 mitogen-activated protein kinase and
iCa2D, respectively
Because A2B AR signaled through cAMP in NHEK, we evalu-
ated the effect of the adenylyl cyclase activator forskolin on
keratinocyte cell growth. In contrast to the effect of adenosine
and BAY, forskolin highly increased proliferation (Figure 2a
and b), suggesting that other signaling pathways rather than
cAMP mediate the cell cycle arrest induced by A2B activation
in NHEK. To determine the possible participation of down-
stream targets to the cAMP signaling cascade, cells were
incubatedwith the protein kinase A inhibitor H-89 (10 mmol/L)
and the exchange protein activated by cAMP (EPAC) ESI-09
(10 mmol/L). Unfortunately, both inhibitors showed toxicity,
determined by lactate dehydrogenase and trypan blue exclu-
sion (data not shown) to warrant reliable results.
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Figure 1. Basal mRNA expression of
ARs in NHEK and intracellular cAMP
and calcium levels after AR
stimulation. (a) Quantitative real-time
reverse transcriptase-PCRdetermination
of AR levels in NHEK. Data are mean
standard error of themean (n¼ 10e12).
Values were normalized to the
housekeeping gene GAPDH. (b) cAMP
levels after 15-minute stimulation with
CGS-21680 (A2A selective), BAY60
e6583 (A2B selective), or NECA
(nonselective), alone or in combination
with the antagonists SCH-442416 (A2A
selective) andMRS-1706 (A2B selective).
Data are mean standard error of the
mean (n ¼ 6e9). ***P < 0.001 versus
basal (nonstimulated NHEK) using
Dunnett t test. ##P< 0.01, ###P< 0.001
using Student t test. (c) Representative
measurement (n ¼ 10) of intracellular
calcium release after stimulation with
AR agonists (arrows) with or without
antagonists. CGS, BAY, and NECA
were tested at 10 mmol/L. SCH andMRS
were pre-incubated for 30 minutes at 1
mmol/L. AR, adenosine receptor; BAY,
BAY60e6583; CGS, CGS-21680; F/F0,
fluorescence signal relative to starting
signal; GAPDH, glyceraldehyde-
3-phosphate dehydrogenase;
MRS, MRS-1706; NECA, 5’-N-
ethylcarboxamidoadenosine;
NHEK, normal human epidermal
keratinocyte; s, seconds; SCH,
SCH-442416.
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Adenosine Receptors on Keratinocyte FunctionAs stated before, AR activate additional signaling pathways
apart from Gs proteins, such as extracellular signal-regulated
kinases and p38 mitogen-activated protein kinase or Gq-
mediated increase of iCa2þ (Aherne et al., 2011). Given the
pivotal role of these signaling pathways in the control of the
cell cycle, we pre-incubated NHEK with the selective
inhibitors PD98059 (extracellular signal-regulated kinase 1/
2), SB202190 (p38), or the calcium chelator 1,2-Bis(2-ami-
nophenoxy)ethane-N,N,N0,N0-tetraacetic acid tetrakis(ace-
toxymethyl ester) (BAPTA-AM) and determined the cell cycle
distribution after 24-hour stimulation with AR agonists. All
these inhibitors did not affect cell cycle at the concentrations
assayed (see Supplementary Figure S2 online). BAPTA-AM
significantly reversed the antiproliferative effect of adeno-
sine (Figure 3a) and BAY (Figure 3b), decreasing the propor-
tion of cells in G1 and suggesting that calcium mediates, at
least in part, the partial cell cycle arrest induced by A2B
activation. On the other hand, the p38 inhibitor SB202190
partially blocked the effect of A2A AR activation, reversing the
increased fraction of cells in the G2/M phase induced by CGS
(Figure 3c).
Adenosine and AR agonists inhibit the inflammatory
response of NHEK
Epidermal keratinocytes are key participants in innate or
adaptive immune responses through production of cytokinesand chemokines such as tumor necrosis factor (TNF)-a or IL-8
(Lowes et al., 2014) and adenosine is a well-established
regulator of inflammation (Hasko´ and Cronstein, 2013).
Therefore, we determined the effect of AR activation on
cytokine release by NHEK stimulated with the protein kinase
C activator TPA, which can reproduce certain inflammatory
parameters of psoriatic skin in animal models (Andres et al.,
2013). Adenosine, as well as the selective A2A and A2B
agonists, inhibited the levels of TNF-a and IL-8 in a
concentration-dependent manner; however, this effect was
not reversed by any of the selective antagonists (Figure 4).
These results suggested an unspecific anti-inflammatory
mechanism independent of ARs. This controversial point
has been previously reported in other cell types such as
neutrophils and macrophages, indicating that adenosine can
suppress cell activation and TNF-a release by other inde-
pendent mechanisms such as the activation of membrane
phosphatases (Fotheringham et al., 2004; Hasko´ and
Cronstein, 2004; Kreckler et al., 2009). In this sense, pre-
incubation of NHEK with the serine/threonine protein phos-
phatase inhibitor okadaic acid enhanced TNF-a release
induced by the protein kinase C activator TPA as previously
described (Fujiki et al., 2013). Nevertheless, in the presence
of okadaic acid, all tested AR agonists failed to inhibit cyto-
kine release after TPA stimulation (see Supplementary
Figure S3 online).www.jidonline.org 125
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Figure 2. Effect of adenosine receptor stimulation on NHEK cell growth.
(a) Proliferation was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay after 48 hours of treatment. Data are
mean absorbance at 490 nm  standard error of the mean (n ¼ 8e10). *P <
0.05, **P < 0.01, ***P < 0.001 versus basal cells (nonstimulated) using
Dunnett t test. #P < 0.05, ###P < 0.001 using Student t test. (b) Results of cell-
cycle analysis by flow cytometry after 24 hours of treatment. Data are mean 
standard error of the mean (n ¼ 10e12). *P < 0.05, **P < 0.01, ***P < 0.001
versus the same distribution phase in the basal cell cycle (Dunnett t test).
CGS-21680, BAY60e6583, adenosine, and NECA were tested at 1 mmol/L.
The antagonists SCH-442416 (A2A selective) and MRS-1706 (A2B selective)
were pre-incubated for 30 minutes at 1 mmol/L. The adenylyl cyclase activator
forskolin was tested at 50 mmol/L. ADO, adenosine; BAY, BAY60e6583; CGS,
CGS-21680; Forsk, forskolin; MRS, MRS-1706; NECA, 5’-N-
ethylcarboxamidoadenosine; NHEK, normal human epidermal keratinocyte;
ns, not significant; SCH, SCH-442416.
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126Inflammatory milieu could alter AR expression in NHEK and
psoriatic epidermis
Several reports have described that the constant exposure of
inflammatory cytokines modulate AR expression in both
infiltrating and resident cells (Khoa et al., 2001; Morello
et al., 2006; Nguyen et al., 2003; Xaus et al., 1999).
Consequently, we hypothesized that the inflammatory milieu
characteristic of psoriatic plaques could alter AR expressionJournal of Investigative Dermatology (2017), Volume 137in NHEK. To assess this hypothesis, we determined mRNA
levels of A2A and A2B receptors in NHEK preincubated with
an array of pro-inflammatory cytokines known to be up-
regulated in psoriasis (TNF-a, IL-1b, IL-6, IL-17, IL-23, IFN-
a, or IFN-g) or with the protein kinase C activator TPA. We
observed that IFN-g, and the reference stimulus TPA, altered
the expression of both ARs, decreasing A2B and increasing
A2A. On the other hand, IFN-a significantly decreased A2B AR
expression, whereas TNF-a and IL-1b increased A2A AR.
Other psoriatic mediators such as IL-6, IL-17, and IL-23 had
no effect (Figure 5a). In view of these results, we next
compared the pattern of AR expression in epidermis obtained
from biopsy samples of plaque-type psoriasis versus
epidermis from surgical foreskin resections of healthy donors,
used throughout this study as the source of NHEK. In healthy
epidermis, AR expression was similar to the one described
earlier for NHEK (Figure 5b). However, even though A2B
continued to be more expressed than A2A, and A1 and A3
were undetectable in psoriatic epidermis, we observed a
significantly different level of expression of both receptor
subtypes compared with normal epidermis: A2B receptor
expression was reduced, whereas A2A receptor mRNA was
increased (Figure 5b). Accordingly, immunoblotting analysis
confirmed that psoriatic epidermis showed higher expression
of A2A and lower expression of A2B ARs than foreskin
epidermis at the protein level, despite a certain degree of
interindividual variability (Figure 5c), possibly because of
receptor glycosylation, as previously reported (Linden et al.,
1999). Therefore, these results suggest that some inflamma-
tory mediators generated in psoriatic skin could deregulate
the normal ratio of AR expression in epidermis and conse-
quently alter the physiological role of AR in keratinocytes.
DISCUSSION
In this study we have elucidated the contribution of AR in
controlling keratinocyte proliferation, resolving a long-lasting
controversy. We have determined that adenosine promotes
cell-cycle arrest, in agreement with older reports (Brown
et al., 2000; Cook et al., 1995); however, using much
lower concentrations and selective antagonists, we have
shown the involvement of A2B AR. On the other hand, we
have shown that A2A AR enhances keratinocyte proliferation,
mediating the proliferative effect of the nonselective agonist
NECA described by Braun et al. (2006). Therefore, our study
underlines the importance of the selection of the right
pharmacological tools.
It is generally believed that A2B AR is a low-affinity receptor,
requiring pathophysiological concentrations of adenosine for
activation (Hasko´ et al., 2009). However, in many cell types,
potency or affinity is markedly influenced by receptor number
and the measured response (Fredholm et al., 2011). Our
results suggest a predominant role for the highly expressed
A2B AR subtype in the physiological control of cell growth in
NHEK, in contrast to other skin resident cells such as fibro-
blasts with higher expressions of A2A AR, whose activation
increases cell proliferation and collagen synthesis (Perez-Aso
et al., 2014; Perez-Aso et al., 2013; Rathbone et al., 1992).
Similar results have been obtained in other cell types where
A2B is the most expressed AR (Dubey et al., 2015; Jackson,
2011; Mayer et al., 2011). In particular, epithelial-specific
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Figure 3. Effect of mitogen-activated protein kinase inhibition or
intracellular calcium chelation on cell cycle phase distribution after
treatment of normal human epidermal keratinocytes with adenosine
receptor agonists. After a 30-minute pretreatment with the extracellular
signal-regulated kinase 1/2 mitogen-activated protein kinase inhibitor
PD98059, the p38 mitogen-activated protein kinase inhibitor SB202190, or
the calcium chelator BAPTA-AM, NHEK were incubated for 24 hours with (a)
the physiological agonist adenosine, (b) the selective A2B agonist
BAY60e6583, or (c) the selective A2A agonist CGS-21680. Data are mean 
standard error of the mean (n ¼ 10e12). **P < 0.01, ***P < 0.001 versus the
same distribution phase in the corresponding control agonist treatment
(Dunnett t test). ADO, adenosine; BAY, BAY60e6583; CGS, CGS-21680;
BAPTA-AM, 1,2-Bis(2-aminophenoxy)ethane-N,N,N0,N0-tetraacetic acid
tetrakis(acetoxymethyl ester); M, mol/L.
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Adenosine Receptors on Keratinocyte FunctionA2B AR mediated the protective effect of adenosine in intes-
tinal inflammation by promoting epithelial barrier (Aherne
et al., 2015).
Our results also indicate that intracellular calcium medi-
ates the antiproliferative effect of A2B AR activation on NHEK,with no involvement of cAMP. Calcium regulates the growth,
differentiation, and apoptosis of many cell types, including
epidermal keratinocytes, in which it induces G1/G0 cell cycle
arrest (Bikle et al., 2012). Thus, some antipsoriatic drugs such
as 1a,25-dihydroxyvitamin D3 or fumaric acid exert an
antiproliferative effect mediated by iCa2þ elevation (Dascalu
et al., 2000). In contrast to the A2B-mediated antiproliferative
effect of adenosine, activation of A2A AR induces a prolifer-
ative response in NHEK dependent on p38 and independent
of cAMP. This observation is in agreement with several
reports stating that the peculiar long C-terminus of A2A AR is
involved in independently signaling through either mitogen-
activated protein kinase or Gs, depending on the membrane
lipid microenvironment (Charalambous et al., 2008; Klinger
et al., 2002).
We have recently shown that topical application of CGS
increased keratinocyte and fibroblast proliferation when
applied topically on uninvolved mouse skin but abrogated
TPA-induced epidermal hyperplasia, mainly because of its
marked anti-inflammatory effect (Arasa et al., 2014). In this
study, we have shown that CGS and the other AR agonists
show anti-inflammatory properties in NHEK. However, this
effect appears to be independent of receptor activation,
because the reduction of cytokine release by both selective
and nonselective AR agonists could not be reversed by their
corresponding AR antagonist. In this regard, we have iden-
tified a possible mechanism related to serine/threonine pro-
tein phosphatase activation, as previously reported for
adenosine in other cellular lineages (Fotheringham et al.,
2004; Kreckler et al., 2009).
Some observations suggest that purine metabolism could
be defective in skin autoimmune diseases such as psoriasis
(Kiehl and Ionescu, 1992; Kose et al., 2001); overexpression
of A2A and A3 AR in inflammatory cells has been found in
different autoimmune disorders (Ochaion et al., 2009;
Varani et al., 2011). In this study, we have observed a
reduction in A2B AR expression besides the increased
expression of A2A AR in psoriatic epidermis. Furthermore,
some inflammatory mediators released during the psoriatic
process could be in part responsible for these variations,
particularly cytokines such as IL-1b, TNF-a, IFN-a, and IFN-
g, which are mainly involved in the initiation of the psori-
atic plaque (Perera et al., 2012). Moreover, such cytokines
as IL-1b and TNF-a have been shown to regulate A2A AR
function as well by preventing its desensitization (Khoa
et al., 2006).
On the other hand, the IL-17/IL-23 axis cytokines, char-
acteristic of the established psoriatic plaque, had no effect.
Therefore, it seems reasonable to think that the variations in
AR expression could occur during the early stages of lesion
development. In this regard, the up-regulation of A2A AR by
TNF-a and Il-1b could play a protective anti-inflammatory
role, as other researchers have suggested (Borea et al.,
2016). Otherwise, IFN-a produced by plasmacytoid den-
dritic cells is one of the key and initial steps in psoriasis
pathogenesis contributing to keratinocyte proliferation
(Farkas and Kemeny, 2012). Thus, the reduction of A2B
expression after stimulation with IFN-a could cause the loss
of the antiproliferative control elicited by this receptor sub-
type in NHEK. However, further experiments comparingwww.jidonline.org 127
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Figure 4. Inhibitory effect of
adenosine receptor agonists on TNF-a
and IL-8 release in normal human
epidermal keratinocytes. Cells were
incubated for 30 minutes with
adenosine, the selective A2A agonist
CGS-21680, or the selective A2B
agonist BAY60e6583 before
stimulation for 7 hours with TPA
(1 mg/ml). Pretreatment with the A2A
antagonist SCH-442416 or the A2B
antagonist MRS-1706 was performed
for 30 minutes before the addition of
the agonist. (aec) TNF-a and (def) IL-
8 levels were determined in cell
supernatants by ELISA. Values are
expressed as mean  standard error of
the mean (n¼ 8e14). *P < 0.05, **P<
0.01, ***P < 0.001 versus the
untreated TPA-stimulated cells using
Dunnett t test. ADO, adenosine; BAY,
BAY60e6583; CGS, CGS-21680; M,
mol/L; MRS, MRS-1706; SCH, SCH-
442416; TNF, tumor necrosis factor;
TPA, 12-O-tetradecanoylphorbol-13-
acetate.
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128lesional to nonlesional psoriatic skin will need to be
conducted to confirm this hypothesis.
This study has shown an intriguing dual role of A2A and A2B
ARs on keratinocyte proliferation and their possible deregu-
lation in psoriatic epidermis. The consequences of the altered
AR expression on adenosine effects in psoriatic keratinocytes
will need to be assessed in further studies, given the high
potential of this endogenous mediator to ameliorate inflam-
matory diseases. Our results suggest that adenosine plays an
important role in regulating epidermal inflammation and
keratinocyte function and thus may constitute an interesting
therapeutic strategy for inflammatory hyperproliferative skin
diseases such as psoriasis.
MATERIALS AND METHODS
Statement on use of human materials
All protocols and procedures were approved by the University of
Valencia Ethical Committee and conformed to the Helsinki guide-
lines. Patient consent for experiments was not required, becauseJournal of Investigative Dermatology (2017), Volume 137Spanish laws consider human tissue left from surgery as discarded
material.
Isolation, culture, and stimulation of primary human
keratinocytes
Primary human keratinocytes were isolated from foreskins of healthy
young donors as described previously (Andres et al., 2013). Briefly,
skin samples were treated with a dispase solution and trypsinized.
Keratinocytes were grown (37 C/5% CO2) in a serum-free low-Ca
2þ
(<0.1 mol/L) Defined Keratinocyte-SFM (Invitrogen, Carlsbad, CA).
For all experiments, cells were seeded at passage numbers 1e3 and
treated upon reaching 60e80% confluence. The day before the
experiments, medium was replaced to growth factor-free keratino-
cyte medium.
Adenosine agonists and antagonists
AR agonists and antagonists (see Supplementary Table S1) were
purchased from Tocris (Bristol, UK) and dissolved in DMSO. The
concentration of DMSO in all experiments was less than 0.1%. In all
the experiments, antagonists were added 30 minutes before agonists.
Figure 5. Differential expression of
adenosine receptors in normal and
psoriatic epidermis. (a) Normal
human epidermal keratinocytes were
incubated with TNF-a, IL-23, IL-17,
IL-1b (10 ng/ml), IFN-g, IFN-a, IL-6
(50 ng/ml), or TPA (1 mg/ml) for 3
hours. Subsequently, mRNA levels of
A2A and A2B adenosine receptors were
evaluated by quantitative real-time
reverse transcriptase-PCR. Data are
mean  standard error of the mean
(n ¼ 6e8). *P < 0.05, ***P < 0.001
versus nontreated normal human
epidermal keratinocytes using
Dunnett t test. All values were
normalized to the housekeeping gene
GAPDH. (b) Variation of A2A and A2B
AR mRNA expression in psoriatic
versus normal epidermis. Data are
mean  standard error of the mean
(n ¼ 10e12). *P < 0.05, ***P < 0.001
using the Mann-Whitney test. (c) A2A
and A2B AR inmmunoblotting of
whole tissue homogenates of
normal (N1eN3) and psoriatic
epidermis (P1eP3). B, nontreated
normal human epidermal
keratinocytes; GAPDH,
glyceraldehyde-3-phosphate
dehydrogenase; TNF, tumor
necrosis factor; TPA, 12-O-
tetradecanoylphorbol-13-acetate.
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NHEK seeded in 24-well plates were stimulated with AR agonist
for 15 minutes. Cells were harvested, and intracellular cAMP
was assessed using Cyclic AMP Direct EIA Kit (Arbor Assays,
Ann Arbor, MI).
iCa2D determination
iCa2þ was assessed using Fluo-4 NW Calcium assay kit (Invitrogen,
Carlsbad, CA), following the manufacturer’s recommendations.
Briefly, NHEK seeded in 96-well plates were incubated for 1 hour
with the dye loading solution and were stimulated with AR agonists
(10 mmol/L). Fluorescence was measured at different time points
using a Wallac 1420 VICTOR2 (PerkinElmer, Waltham, MA).
Proliferation assay
NHEK were seeded in a 12-well plate and incubated for 48 hours
with AR agonists (1 mmol/L) in growth factor-free keratinocyte me-
dium. Cell density was determined by MTT reduction, and cyto-
toxicity was assessed by measuring lactate dehydrogenase release in
the supernatants (Andres et al., 2013).
Cell cycle assay
AR agonists (1mmol/L) were added to NHEK cultured in 25 cm2-
flasks with growth factor-free keratinocyte medium. After 24 hours,
cells were trypsinized, and cell cycle was measured using BDCycletes Plus DNA Reagent Kit (BD Biosciences, San Jose, CA).
Results were analyzed using a BD FACS VERSE cytometer (BD
Biosciences).
Determination of cytokine release
NHEK seeded in 24-well plates were incubated with AR agonists for
30 minutes before stimulation with TPA from Sigma-Aldrich (St.
Louis, MO). After 7-hour supernatants were collected. TNF-a, (R&D
Systems, Abingdon, UK) and IL-8 (eBioscience, San Diego, CA)
levels were assessed in cell supernatants using ELISA assays,
following standard manufacturer protocols.
Determination of AR expression
Lesional psoriatic skin was obtained from punch biopsy from the
center of a plaque-type psoriatic lesion at time of diagnosis. For the
quantitative real-time reverse transcriptase-PCR determination, 12
patients (mean age  standard deviation ¼ 42.5  6.5 years, white,
8 men and 4 women) and, for the immunoblotting analysis, 8 pa-
tients (mean age  standard deviation ¼ 39.4  5.4 years, white
men) were included in this study.
RNA isolation, and quantitative real-time reverse tran-
scriptaseePCR were performed in isolated NHEK cells and normal
and psoriatic epidermis following the manufacturer’s specifications.
NHEK cells were stimulated with TNF-a, IL-1b, IL-17, IL-23www.jidonline.org 129
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130(10 ng/ml), IL-6, IFN-a, IFN-g (50 ng/ml), or TPA (1 mg/ml) for 3
hours. All cytokines were from PeproTech (London, UK) except IL-
6 (R&D Systems, Abingdon, UK). Tripure Isolation Reagent (Roche,
Mannheim, Germany) and ImRrom-II Reverse Transcription System
(Promega, Madison, WI) were used for construction of cDNA,
including random hexamers as primers. Subsequently, mRNA
expressions of A1, A2A, A2B, A3, and the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase were determined
using TaqMan MGB probes, FAM dye-labeled gene expression
assay mix (assay ID: Hs00379752_m1, Hs00169123_m1,
Hs00386497_m1, Hs00181232_m1, and Hs99999905_m1,
respectively) and Taqman Universal Master Mix II (Applied Bio-
systems, Foster City, CA). All samples were analyzed in doublets
on a StepOnePlus (Applied Biosystems, Foster City, CA). Relative
gene expression levels were determined by using the quantitative
CT method.
Western blot of homogenized skin biopsy samples (20 mg of
protein) was performed as previously described (Arasa et al., 2014).
Specific antibodies against A2A and A2B AR were from Alomone labs
(Jerusalem, Israel). Secondary staining was obtained by incubating
with goat anti-rabbit antibody (Dako, Glostrup, Denmark). Glycer-
aldehyde-3-phosphate dehydrogenase was used as the reference
protein for loading control.
Statistical analysis
Results are presented as mean  standard error of the mean; n
represents the number of experiments. The level of statistical sig-
nificance was determined by analysis of variance, followed by the
Dunnett t test for multiple comparisons, Student t test, or Mann-
Whitney test for dual comparisons. All statistical analyses were
performed using GraphPad Prism 6 software (GraphPad Software,
Inc., San Diego, CA). Significance was assumed at a P-value of 0.05
or less.
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